Multi-Institutional Phase II Clinical Study of Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer in East and Southeast Asia

ATL: Results of a Multi-Institutional Phase 2 Study (JGOG1066)

“…They demonstrated favorable compliance in Asian patients. 25 The present results are not consistent with the results of some phase 1 studies. 15,26 As in one Japanese phase 1 study, South African investigators reported the same maximum tolerated dose of 30 mg/m 2 in their study.…”

“…However, good compliance has been also reported from other Asian countries. 7,10 Kato et al 25 reported data from an international multi-institutional phase 2 study of CCRT promoted in Asian countries. They demonstrated favorable compliance in Asian patients.…”

Daily Low-Dose Cisplatin-Based Concurrent Chemoradiotherapy in Patients With Uterine Cervical Cancer With Emphasis on Elderly Patients

“…In an Asian phase 2 study of weekly CCRT, the corresponding rates were 25% and 7%, respectively. 13 In Gynecologic Oncology Group 120, these rates were reported to be 23% and 12% in the radiation-plus-cisplatin arm, respectively, and 46% and 18% in the radiation-plus-cisplatin and 5-fluorouracil arm, respectively. 3 Compared with those reported in other studies, the rates of leukopenia in our study tended to be higher, but nonhematological toxicities were similar.…”

Multicentre dose audit for clinical trials of radiation therapy in Asia

“…Multicentre clinical trials have been conducted within the framework of the Forum for Nuclear Cooperation in Asia (FNCA) to develop and establish effective strategies of medical care for common malignant tumours (such as carcinoma of the uterine cervix and nasopharyngeal cancer) in Asian countries [1–6]. The FNCA is a framework of regional cooperation between Asian countries with the aim of promoting peaceful and safe application of nuclear science and technology.…”